Want to see HK:2196 full AI Analyst Report?
Top Page
Shanghai Fosun Pharmaceutical (Group) Co
(2196)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$17.00
â–Ľ(-13.40% Downside)
Action:Reiterated
Date:04/30/26
The score is driven primarily by improving fundamentals (strong TTM revenue rebound and steady profitability) but held back by weak cash conversion and only average returns with moderate leverage. Technical indicators are neutral-to-soft with the stock trading below key longer-term moving averages, while valuation looks fair with a moderate P/E and a modest dividend yield.
Positive Factors
Diversified business model
Fosun Pharma's multi-segment model (manufacturing, distribution, and healthcare services) creates durable revenue diversification across product sales, distribution margins and service fees. This reduces single-product concentration risk and supports steadier cash flows across cycles.
Negative Factors
Weak cash conversion
Earnings are not converting efficiently into cash: FCF at ~24% of net income and a volatile FCF history mean reported profits may overstate available internally generated resources. This limits durable capacity for dividends, buybacks or large organic investments without raising external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified business model
Fosun Pharma's multi-segment model (manufacturing, distribution, and healthcare services) creates durable revenue diversification across product sales, distribution margins and service fees. This reduces single-product concentration risk and supports steadier cash flows across cycles.
Read all positive factors
Shanghai Fosun Pharmaceutical (Group) Co (2196) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$67.27B
Dividend Yield1.69%
Average Volume (3M)8.63M
Price to Earnings (P/E)18.2
Beta (1Y)1.10
Revenue Growth1.52%
EPS Growth22.54%
CountryHK
Employees40,603
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.61
Shares Outstanding551,940,500
10 Day Avg. Volume5,166,409
30 Day Avg. Volume8,626,817
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio60.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$25.23Price Target Upside28.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)1.47
Revenue Forecast (FY)HK$43.67B
Shanghai Fosun Pharmaceutical (Group) Co Business Overview & Revenue Model
Company Description
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of p...
How the Company Makes Money
Fosun Pharma generates revenue primarily through a multi-segment model: (1) Pharmaceutical manufacturing and commercialization: the company earns product sales revenue by selling proprietary and partnered pharmaceutical products to hospitals, phar...
Shanghai Fosun Pharmaceutical (Group) Co Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
63
Positive
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 51.75B | 40.42B | 41.07B | 41.40B | 43.95B | 39.01B |
| Gross Profit | 25.90B | 20.16B | 19.70B | 19.68B | 20.78B | 18.78B |
| EBITDA | 6.03B | 6.16B | 8.60B | 7.55B | 7.87B | 8.70B |
| Net Income | 4.27B | 3.28B | 2.77B | 2.39B | 3.73B | 4.73B |
Balance Sheet | ||||||
| Total Assets | 122.97B | 120.07B | 117.46B | 113.47B | 107.16B | 93.29B |
| Cash, Cash Equivalents and Short-Term Investments | 15.29B | 15.78B | 16.12B | 15.58B | 17.17B | 14.55B |
| Total Debt | 31.86B | 36.66B | 31.70B | 30.28B | 30.25B | 24.25B |
| Total Liabilities | 59.30B | 58.24B | 57.53B | 56.85B | 53.05B | 44.92B |
| Stockholders Equity | 49.15B | 48.72B | 47.26B | 45.68B | 44.58B | 39.19B |
Cash Flow | ||||||
| Free Cash Flow | 884.92M | 764.78M | 66.79M | -1.92B | -1.67B | -1.02B |
| Operating Cash Flow | 5.31B | 5.21B | 4.48B | 3.41B | 4.22B | 3.95B |
| Investing Cash Flow | -3.69B | -2.15B | -3.61B | -3.82B | -4.06B | -3.86B |
| Financing Cash Flow | -1.33B | -3.24B | -1.00B | -1.34B | 4.43B | -831.28M |
Shanghai Fosun Pharmaceutical (Group) Co Technical Analysis
Neutral
19.63
Price Trends
16.93
Negative
18.34
Negative
20.41
Negative
Market Momentum
-0.11
Negative
52.69
Neutral
66.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2196, the sentiment is Neutral. The current price of 19.63 is above the 20-day moving average (MA) of 15.96, above the 50-day MA of 16.93, and below the 200-day MA of 20.41, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 52.69 is Neutral, neither overbought nor oversold. The STOCH value of 66.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2196.
Shanghai Fosun Pharmaceutical (Group) Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$197.21B | 30.25 | 16.71% | 0.97% | 22.62% | 26.23% | |
72 Outperform | HK$28.53B | 13.87 | 13.95% | 4.09% | 1.48% | -1.55% | |
61 Neutral | HK$30.13B | 17.47 | 8.65% | 2.26% | 10.00% | -7.54% | |
58 Neutral | HK$67.27B | 18.22 | 7.19% | 1.69% | 1.52% | 22.54% | |
58 Neutral | HK$28.59B | 6.51 | 7.98% | 2.95% | 4.66% | 20.76% | |
56 Neutral | HK$38.95B | 12.12 | 7.70% | 7.15% | 7.32% | 12.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
16.55
-0.20
-1.21%
HK:0867
China Medical System Holdings
12.33
-0.43
-3.35%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
15.47
-1.44
-8.49%
HK:1513
Livzon Pharmaceutical Group
26.14
-4.54
-14.81%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.62
-0.42
-8.35%
HK:3692
Hansoh Pharmaceutical Group Company Limited
32.56
-0.41
-1.24%
Shanghai Fosun Pharmaceutical (Group) Co Corporate Events
Fosun Pharma Wins NMPA Nod for FXR0906 Hypertriglyceridemia Trial
Jul 15, 2026
Shanghai Fosun Pharmaceutical’s subsidiary Fosun Pharmaceutical Industrial Development (Shenzhen) has obtained approval from China’s National Medical Products Administration to begin clinical trials of FXR0906, a liver-targeted siRNA t...
Fosun Pharma Subsidiary Wins Approval for New Traditional Chinese Medicine Granules
Jun 29, 2026
Shanghai Fosun Pharmaceutical said its subsidiary Hebei Wanbang Folon Pharmaceutical has received approval from China’s National Medical Products Administration for Shaoyao Gancao Tang Granules, a Class 3.1 traditional Chinese medicine. The ...
Fosun Pharma Moves Ahead With Spin-Off Listing of Fosun Adgenvax in Hong Kong
Jun 26, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. plans to spin off its subsidiary Fosun Adgenvax for a separate listing of H shares on the Main Board of the Hong Kong Stock Exchange, while retaining it as a subsidiary. The proposed issuance will in...
Fosun Pharma Shareholders Back AGM Resolutions and Final Dividend
Jun 16, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a major Chinese pharmaceutical and healthcare group listed in both A-share and H-share markets, held its annual general meeting and separate class meetings for A and H shareholders in Shanghai on 16...
Fosun Pharma Sets Final 2025 Dividend and Withholding Tax Terms for H-Share Investors
Jun 16, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has declared a final ordinary cash dividend of RMB 0.39 per share for the financial year ended 31 December 2025, with approval obtained on 16 June 2026. For H-share holders registered in Hong Kong, t...
Fosun Pharma Wins NMPA Approval for New Pediatric Use of Luvometinib
Jun 15, 2026
Shanghai Fosun Pharmaceutical has announced that its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development, has received approval from China’s National Medical Products Administration for an additional indication of its drug Luvom...
Fosun Pharma Subsidiary Wins China Approval for Broad-Spectrum Levofloxacin Injection
May 21, 2026
Shanghai Fosun Pharmaceutical has announced that its subsidiary Yaopharma Co., Ltd. has received approval from China’s National Medical Products Administration for Levofloxacin Injection, a chemical Class 3 generic. The broad-spectrum antibi...
Fosun Pharma Subsidiary Wins NMPA Acceptance for Innovative TCM Women’s Health Drug
May 13, 2026
Shanghai Fosun Pharmaceutical announced that the National Medical Products Administration has accepted a drug registration application filed by its subsidiary Hebei Wanbang Folon Pharmaceutical for Tao Hong Si Wu Tang Granules. The move underlines...
Fosun Pharma Sets AGM to Approve 2025 Results and New Capital Mandates
May 11, 2026
Shanghai Fosun Pharmaceutical has called its 2026 annual general meeting for 16 June in Shanghai, where shareholders will review the group’s 2025 performance, including the annual report, board work report, profit distribution proposal, and ...
Fosun Pharma Calls 2026 H Shareholders Meeting on New H-Share Buyback Mandate
May 11, 2026
Shanghai Fosun Pharmaceutical has called a 2026 second H shareholders class meeting to be held in Shanghai on 16 June 2026, immediately after its AGM and A shareholders class meeting. The session will ask H shareholders to consider special resolut...
Fosun Pharma Subsidiary Wins China Approval for Venlafaxine SR Tablets
May 8, 2026
Shanghai Fosun Pharmaceutical said a key subsidiary, Fosun Pharma (Xuzhou) Co., Ltd., has obtained approval from China’s National Medical Products Administration to market Venlafaxine Hydrochloride Sustained-release Tablets. The product, a C...
Fosun Pharma Subsidiary Wins Approval for Sodium Nitroprusside Injection
Apr 30, 2026
Shanghai Fosun Pharmaceutical announced that its subsidiary Yaopharma Co., Ltd. has received approval from the National Medical Products Administration for the drug registration of Sodium Nitroprusside Injection. The product is indicated for hyper...
Fosun Pharma Files Unaudited First-Quarter 2026 Report in Line With Hong Kong Rules
Apr 28, 2026
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has released its unaudited first quarterly report for 2026, covering the three months ended 31 March 2026 and prepared under PRC Accounting Standards for Business Enterprises. The announcement, issue...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.